Toward elimination of mother-to-child transmission of HIV in Malawi: Findings from the Malawi Population-based HIV Impact Assessment (2015-2016).
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
07
2021
accepted:
11
08
2022
entrez:
1
9
2022
pubmed:
2
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
Malawi spearheaded the development and implementation of Option B+ for prevention of mother-to-child transmission of HIV (PMTCT), providing life-long ART for all HIV-positive pregnant and breastfeeding women. We used data from the 2015-2016 Malawi Population-based HIV Impact Assessment (MPHIA) to estimate progress toward 90-90-90 targets (90% of those with HIV know their HIV-positive status; of these, 90% are receiving ART; and of these, 90% have viral load suppression [VLS]) for HIV-positive women reporting a live birth in the previous 3 years. MPHIA was a nationally representative household survey; consenting eligible women aged 15-64 years were interviewed on pregnancies and outcomes, including HIV status during their most recent pregnancy, PMTCT uptake, and early infant diagnosis (EID) testing. Descriptive analyses were weighted to account for the complex survey design. Viral load (VL) results were categorized by VLS (<1,000 copies/mL) and undetectable VL (target not detected/below the limit of detection). Of the 3,153 women included in our analysis, 371 (10.1%, 95% confidence interval [CI]: 8.8%-11.3%) tested HIV positive in the survey. Most HIV-positive women (84.2%, 95% CI: 79.9%-88.6%) reported knowing their HIV-positive status; of these, 94.9% (95% CI: 91.7%-98.2%) were receiving ART; and of these, 91.2% (95% CI: 87.4%-95.0%) had VLS. Among the 371 HIV-positive women, 76.0% (95% CI: 70.4%-81.7%) had VLS and 66.5% (95% CI: 59.8%-73.2%) had undetectable VL. Among 262 HIV-exposed children, 50.8% (95% CI: 42.8%-58.8%) received EID testing within 2 months of birth, whereas 17.9% (95% CI: 11.9%-23.8%) did not receive EID testing. Of 190 HIV-exposed children with a reported HIV test result, 2.1% (95% CI: 0.0%-4.6%) had positive results. MPHIA data demonstrate high PMTCT uptake at a population level. However, our results identify some gaps in VLS in postpartum women and EID testing.
Sections du résumé
BACKGROUND
Malawi spearheaded the development and implementation of Option B+ for prevention of mother-to-child transmission of HIV (PMTCT), providing life-long ART for all HIV-positive pregnant and breastfeeding women. We used data from the 2015-2016 Malawi Population-based HIV Impact Assessment (MPHIA) to estimate progress toward 90-90-90 targets (90% of those with HIV know their HIV-positive status; of these, 90% are receiving ART; and of these, 90% have viral load suppression [VLS]) for HIV-positive women reporting a live birth in the previous 3 years.
METHODS
MPHIA was a nationally representative household survey; consenting eligible women aged 15-64 years were interviewed on pregnancies and outcomes, including HIV status during their most recent pregnancy, PMTCT uptake, and early infant diagnosis (EID) testing. Descriptive analyses were weighted to account for the complex survey design. Viral load (VL) results were categorized by VLS (<1,000 copies/mL) and undetectable VL (target not detected/below the limit of detection).
RESULTS
Of the 3,153 women included in our analysis, 371 (10.1%, 95% confidence interval [CI]: 8.8%-11.3%) tested HIV positive in the survey. Most HIV-positive women (84.2%, 95% CI: 79.9%-88.6%) reported knowing their HIV-positive status; of these, 94.9% (95% CI: 91.7%-98.2%) were receiving ART; and of these, 91.2% (95% CI: 87.4%-95.0%) had VLS. Among the 371 HIV-positive women, 76.0% (95% CI: 70.4%-81.7%) had VLS and 66.5% (95% CI: 59.8%-73.2%) had undetectable VL. Among 262 HIV-exposed children, 50.8% (95% CI: 42.8%-58.8%) received EID testing within 2 months of birth, whereas 17.9% (95% CI: 11.9%-23.8%) did not receive EID testing. Of 190 HIV-exposed children with a reported HIV test result, 2.1% (95% CI: 0.0%-4.6%) had positive results.
CONCLUSIONS
MPHIA data demonstrate high PMTCT uptake at a population level. However, our results identify some gaps in VLS in postpartum women and EID testing.
Identifiants
pubmed: 36048781
doi: 10.1371/journal.pone.0273639
pii: PONE-D-21-23629
pmc: PMC9436140
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0273639Subventions
Organisme : PEPFAR
Pays : United States
Organisme : CGH CDC HHS
ID : U2G GH001226
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Public Health Action. 2017 Jun 21;7(2):83-89
pubmed: 28695079
Bull World Health Organ. 2012 Sep 1;90(9):699-704
pubmed: 22984315
PLoS One. 2015 May 05;10(5):e0125525
pubmed: 25942423
MMWR Morb Mortal Wkly Rep. 2013 Mar 1;62(8):148-51
pubmed: 23446514
HIV Med. 2017 Feb;18(2):80-88
pubmed: 27353189
J Int AIDS Soc. 2019 Jun;22(6):e25290
pubmed: 31180186
J Acquir Immune Defic Syndr. 2017 May 1;75 Suppl 1:S43-S50
pubmed: 28398996
PLoS One. 2018 Dec 13;13(12):e0209052
pubmed: 30543685
Pediatr Infect Dis J. 2015 Mar;34(3):273-5
pubmed: 25742076
Lancet HIV. 2018 Dec;5(12):e688-e695
pubmed: 30467022
J Acquir Immune Defic Syndr. 2017 Jun 1;75 Suppl 2:S149-S155
pubmed: 28498184
J Infect Dis. 2011 May 1;203(9):1231-4
pubmed: 21398393
J Int AIDS Soc. 2017 Sep 04;20(1):21947
pubmed: 28884524
Lancet. 2005 Oct 1;366(9492):1182-8
pubmed: 16198767
Rapid Commun Mass Spectrom. 2005;19(21):2995-3001
pubmed: 16193530
AIDS. 2009 Jun 19;23(10):1255-9
pubmed: 19455017
Int J STD AIDS. 2018 Feb;29(2):185-194
pubmed: 28750577
PLoS Med. 2014 Feb 25;11(2):e1001608
pubmed: 24586123
J Int AIDS Soc. 2016 Mar 11;19(1):20672
pubmed: 26976377
J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):417-25
pubmed: 22193774
Bull World Health Organ. 2018 Apr 01;96(4):256-265
pubmed: 29695882
Bull World Health Organ. 2019 Mar 01;97(3):200-212
pubmed: 30992633
Am J Public Health. 2009 Nov;99(11):2079-86
pubmed: 19762662
PLoS One. 2018 Dec 28;13(12):e0209782
pubmed: 30592749